Patents - Global Data - Dimensions
Application
Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
Applicants
- Genmab (Denmark)
[NORA names: Genmab; Private Research; Denmark; Europe, EU; Nordic; OECD]
Abstract
The present invention provides more effective methods and compositions for treating cancers, such as colorectal cancer, non-small cell lung cancer, pancreatic cancer, head and neck cancer, bladder cancer, endometrial cancer, esophageal cancer, and prostate cancer, in a subject. The present invention provides a method for treating cancer in a subject, comprising administering to the subject an antibody-drug conjugate that binds to tissue factor (TF), the antibody-drug conjugate comprising an anti-TF antibody, or an antigen-binding fragment thereof, conjugated to monomethyl auristatin, or a functional analog or derivative thereof, and the antibody-drug conjugate is administered at a dose ranging from about 1.5 mg/kg to about 2.1 mg/kg. [Selected Figure] Figure 2A
Patent Family Records (14)
Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer - Patents.com
Genmab (Denmark), Genmab AS アビドイエ オイウェイル オー．, アビドイエ オイウェイル オー．, サテン デイビッド, (...more)
2024, JP-7471227-B2
Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
Genmab (Denmark), Genmab AS アビドイエ オイウェイル オー．, アビドイエ オイウェイル オー．, サテン デイビッド, (...more)
2024, JP-2024045219-A
ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER
Genmab (Denmark), Genmab AS RANGWALA RESHMA ABDULLA, BREIJ ESTHER CORNELIA WILHELMINA, SATIJN DAVID, (...more)
2021, US-20210030888-A1
Anti-tissue factor antibody-drug conjugate and its use in the treatment of cancer
Genmab (Denmark), Genmab AS アビドイエ オイウェイル オー．, アビドイエ オイウェイル オー．, サテン デイビッド, (...more)
2021, JP-2021515017-A
ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER
Genmab (Denmark), Genmab AS BREIJ ESTHER, SATIJN DAVID, VERPLOEGEN SANDRA, (...more)
2021, EP-3762032-A4
ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER
Genmab (Denmark), Genmab AS BREIJ ESTHER, SATIJN DAVID, VERPLOEGEN SANDRA, (...more)
2021, EP-3762032-A1
ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER
GENMAB AS, Genmab (Denmark) BREIJ ESTHER, SATIJN DAVID, RANGWALA RESHMA ABDULLA, (...more)
2020, SG-11202007865V-A
ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER.
GENMAB AS, Genmab (Denmark) VERPLOEGEN SANDRA, SATIJN DAVID, BREIJ ESTHER, (...more)
2020, MX-2020008613-A
Anti-tissue factor antibody-drug conjugates and their use in cancer treatment
GENMAB A, Genmab (Denmark) RANGWALA RESHMA ABDULLA, BREIJ ESTHER, SATIJN DAVID, (...more)
2020, KR-20200130356-A
ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER
GENMAB AS, Genmab (Denmark)
2020, IL-276768-A
METHOD FOR TREATING CANCER IN A SUBJECT, CASE, USE OF AN ANTIBODY-PHARMACEUTICAL CONJUGATE THAT LINKS TO THE TISSUE FACTOR, AND, ANTIBODY-PHARMACEUTICAL CONJUGATE.
GENMAB AS, Genmab (Denmark) ANDREAS LINGNAU, DAVID SATIJN, ESTHER BREIJ, (...more)
2020, BR-112020018092-A2
Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
Genmab (Denmark), Genmab AS BREIJ ESTHER, SATIJN DAVID, VERPLOEGEN SANDRA, (...more)
2020, AU-2019231696-A1
ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER
GENMAB AS, Genmab (Denmark), RANGWALA RESHMA ABDULLA RANGWALA RESHMA ABDULLA, BREIJ ESTHER, SATIJN DAVID, (...more)
2019, WO-2019173523-A1
ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER
Genmab (Denmark), Genmab AS RANGWALA RESHMA ABDULLA, BREIJ ESTHER, SATIJN DAVID, (...more)
2019, CA-3091217-A1